Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 1, 2010, Pages 1-4

  Awad, A George ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CANNABIS; CHLORPROMAZINE; CLOZAPINE; COCAINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT;

CIGARETTE SMOKING; COFFEE; COMORBIDITY; DEPRESSION; DOPAMINERGIC NERVE CELL; DRUG DEPENDENCE; DRUG TOLERABILITY; DYSPHORIA; EDITORIAL; HUMAN; MOLECULAR INTERACTION; NEUROBIOLOGY; PATIENT SATISFACTION; PSYCHOMETRY; REINFORCEMENT; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT OUTCOME; ADDICTION; ANIMAL; PATIENT COMPLIANCE; PSYCHIATRIC DIAGNOSIS;

ANIMALS; ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; MEDICATION ADHERENCE; PATIENT SATISFACTION; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 77950891328     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.2     Document Type: Editorial

References (41)

1. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr. Bull. 19, 609-618 (1993).
2. Awad AG. Behavioural and subjective side effects. In: Managing The Side Effects Of Drug Therapy In Schizophrenia. Kane J (Ed.). Science Press, London, UK 1-14 (1999).
3. Awad AG, Voruganti L, Heslegrave RJ, Hogan T P. Assessment of the patient's subjective experiences in acute neuroleptic treatment: implications for compliance and outcome. Int. Clin. Psychopharmacol. 11(Suppl. 2), 55-59 (1996).
4. Hogan TP, Awad AG, Eastwood MR. Early subjective response and prediction of outcome to neuroleptic drug therapy. Can. J. Psychiatry 30, 246-248 (1985).
5. Van Putten T, Marder SR. Behavioural toxicity of antipsychotic drugs. J. Clin. Psychiatry 48, 13-19 (1987).
6. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology 171, 121-132 (2004).
7. Awad AG, Hogan TP. Early treatment events and prediction of response to neuroleptic in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 9, 585-588 (1985).
8. Awad AG. Drug therapy in schizophrenia-variability of outcome and prediction of response. Can. J. Psychiatry 34, 711-720 (1989).
9. Hogan TP, Awad AG. Subjective response to neuroleptic and outcome in schizophrenia-are-examination of two measures. Psychol. Med. 22, 347-352 (1992).
10. Weiden PJ, Rapkin B, Mott T et al. Rating of medication infuences (ROMI) scale in schizophrenia. Schizophr. Bull. 20, 297-310 (1994).
11. Naber DA. Self-rating scale to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life and other clinical variables. Int. J. Clin. Psychopharmacol. 10(Suppl. 3), 123-133 (1995).
12. Voruganti L, Awad AG. Personal evaluation of transition in treatment (PETiT): a scale to measure subjective tolerability of antipsychotic medications. Schizophr. Res. 56, 37-46 (2002).
13. Davidhizar RE. Can clients with schizophrenia describe feelings and beliefs about medications? J. Adv. Neurol. 10, 469-473 (1985).
14. Voruganti L, Heselgrave RJ, Awad AG. Seeman M. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol. Med. 28, 165-172 (1998).
15. Awad AG, Voruganti L. The subjective/objective dichotomy; implications for nosology, treatment and research. In: Zukunftsperspek Tiven in Psychiatrie und Psychoterapie-Steinkopff Verlay. Gaebel W (Ed.). Darmstadt, Germany 21-27 (2000).
16. Liraud R, Droulout T, Parrot M, Verdoux H. Agreement between self-rated and clinically assessed symptoms in subjects with psychosis. J. Nerv. Ment. Dis. 192, 352-356 (2004).
17. Naber D, Walther A, Kircher T, Hayek D, Holzbach R. Subjective effects of neuroleptics predict compliance. In: Prediction of Neuroleptic Treatment Outcome in Schizophrenia Concepts and Methods. Gaebel W, Awad AG (Eds). Springer-Verlag, NY, USA 85-98 (1994).
18. Brounie S, Grevan J, Gervin M, Rae M, Larkin C, O'Callaghan E. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J. Nerv. Ment. Dis. 186, 74-78 (1998).
19. Bartko G, Herczeg I, Bekesy M. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. J. Clin. Psychiatry 48, 363-365 (1987).
20. Cabeza IG, Amador MS, Lopez CA, Chavex MG. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr. Res. 41, 349-355 (2000).
21. Swerdlow NR, Koob GF. Dopamine, schizophrenia, manic and depression: towards a unifed hypothesis of cortico-striatal-pallido-thalamic function. Behav. Brain Sci. 10, 197-245 (1987).
22. Caine ED, Polinsky RJ. Haloperidol-induced dysphoria in patients with Tourette syndrome. Am. J. Psychiatry 136, 1216-1217 (1979).
23. Friedenberg DL, Cummings JL. Parkinson's disease, depression and the on-off phenomenon. Psychosomatics 30, 94-99 (1989).
24. Volkow ND, Fowler JS, Wang GJ. Imaging studies on the role of dopamine in cocaine reinforcement and addiction and in humans. J. Psychopharmacol. 13, 337-345 (1999).
25. Laruelle M, Abi-Dargham A, van Dyck CH et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J. Nucl. Med. 36, 1182-1190 (1995).
26. Voruganti L, Slomka P, Zabel P et al. Subjective effects of AMPT induced dopamine depletion in schizophrenia: the correlation between D2 binding ratio and dysphoric responses. Neuropsychopharmacology 25, 642-650 (2001).
27. Voruganti L, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia-fndings from an in vivo SPECT study. Schizophr. Res. 88, 179-186 (2006).
28. Seeman P, Ulpian C, Bergeron C et al. Bimodal distribution of dopamine receptor densities in brains of schizophrenic. Science 225, 728-731 (1984).
29. Hietala J, Syralahti E, Vilkman H et al. Depressive symptoms and pre-synaptic dopamine function in neuroleptic naïve schizophrenia. Schizophr. Res. 35, 41-50 (1999)
30. deHaan L, Lavalaye J, Linszen D, Dingemans PMAJ, Booij J. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am. J. Psychiatry 157, 1019-1020 (2000).
31. Mueser KT, Yarnold PR, Levinson DF. Prevalence of substance abuse in schizophrenia. Demographics and clinical correlates. Schizophr. Bull. 16, 31-54 (1990).
32. Reigier DA, Farner ME, Rae DS. Comorbidity of mental disorder with alcohol and other drugs of abuse. JAMA 264, 2511-2518 (1990).
33. Khantzian E. The self-medication hypothesis of addictive disorders. Am. J. Psychiatry 142, 1259-1264 (1985).
34. Voruganti LNP, Heselgrave RJ, Awad AG. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J. Nerv. Ment. Dis. 186, 74-78 (1998).
35. Awad AG, Voruganti LNP. Neuroleptic dysphoria, comorbid drug abuse in schizophrenia and the emerging science of subjective tolerability-towards a new synthesis. J. Dual Diagnosis 1, 83-93 (2005).
36. Smith MJ, Barch DM, Wof TJ, Mamah D, Csernansky JG. Elevated rates of substance disorders in non-psychotic siblings of individuals with schizophrenia. Schizophr. Res. 106, 294-299 (2008).
37. Chambers AR, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry 50, 71-83 (2001).
38. Koob GF, Moal M. Drug abuse: hedonic homeostatic disregulation. Science 278, 52-58 (1997).
39. Brady K T, Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of stress. Am. J. Psychiatry 126, 1483-1493 (2005).
40. Kosteu TA, Nestler EJ. Clozapine attenuates cocaine conditioned place preference. Life Sci. 55, PL9-PL14 (1994).
41. Noordsy DL, Green AL. Pharmacotherapy for schizophrenia and co-occurring substance use disorder. Curr. Psychiatry Rep. 5, 340-346 (2003).